About BioCardia

We are developing cellular  and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases.

Our Mission: To improve the lives of patients with cardiovascular and pulmonary diseases through the development of meaningful therapeutics

Our Pipeline: Our lead therapeutic candidate is FDA designated "Breakthrough" investigational CardiAMP™ Cell Therapy, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - ischemic heart failure (BCDA-01)  and chronic myocardial ischemia (BCDA-02).

The Company’s second therapeutic platform, its NK1R+ MSC platform, an allogenic NK1 receptor positive mesenchymal stem cell population, an investigational culture expanded bone marrow derived allogenic or “off the shelf” cell therapy using neurokinin-1 receptor positive mesenchymal stem cells for the treatment of heart failure patients (BCDA-03) and acute respiratory distress syndrome (BCDA-04).


Have questions?
: (800) 624-1179
Have questions?
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.